Can Auvelity (dextromethorphan‑bupropion) be used concurrently with an SSRI, and what precautions are required to avoid serotonin syndrome?

Auvelity and SSRI Combination Therapy

Auvelity (dextromethorphan-bupropion) can be used concurrently with SSRIs, but this combination carries significant risk of serotonin syndrome and requires careful monitoring, particularly in the first 24-48 hours after initiation or dose changes.

Understanding the Serotonin Syndrome Risk

The FDA label for Auvelity explicitly warns that concomitant use with SSRIs or tricyclic antidepressants may cause serotonin syndrome, a potentially life-threatening condition 1. This risk stems from dextromethorphan's serotonergic properties—at therapeutic doses in Auvelity, dextromethorphan acts as an NMDA receptor antagonist and sigma-1 receptor agonist, but it also has serotonin reuptake inhibitory activity 2.

Clinical manifestations of serotonin syndrome include:

• Mental status changes (confusion, agitation, anxiety) 2
• Neuromuscular hyperactivity (tremors, clonus, hyperreflexia, muscle rigidity) 2
• Autonomic hyperactivity (hypertension, tachycardia, arrhythmias, tachypnea, diaphoresis, shivering, vomiting, diarrhea) 2
• Advanced symptoms can progress to fever, seizures, arrhythmias, and unconsciousness, which can be fatal 2

Symptoms typically arise within 24 to 48 hours after combining serotonergic medications 2.

Real-World Usage Patterns

Real-world data demonstrates that concurrent use is common in clinical practice. In a large claims database analysis of 22,288 patients initiating Auvelity, 71.2% used it as add-on therapy rather than monotherapy 3. Among those using add-on therapy, Auvelity was most frequently combined with an SSRI alone (10.7% of all patients) or SNRI alone (6.5%) 3. This suggests clinicians are routinely combining these agents despite the theoretical risk.

Evidence-Based Precautions

Pre-Initiation Screening

Before starting Auvelity with an SSRI, screen for:

• Current use of other dextromethorphan-containing products (cough/cold medications) 2, 1
• Current use of other bupropion-containing products 1
• History of seizures (bupropion lowers seizure threshold) 1
• Use of MAOIs (absolute contraindication—requires 14-day washout) 2, 1

Monitoring Protocol

The American Academy of Child and Adolescent Psychiatry guidelines recommend:

• Start the second serotonergic drug at a low dose 2
• Increase the dose slowly 2
• Monitor intensively for symptoms, especially in the first 24 to 48 hours after dosage changes 2

For Auvelity specifically:

• The standard dosing is one tablet twice daily (at least 8 hours apart), with no dose titration required 1
• When adding to existing SSRI therapy, maintain heightened vigilance for the first 48 hours
• Educate patients to immediately report symptoms of confusion, agitation, tremor, muscle rigidity, fever, or rapid heart rate 1

Critical Drug Interaction Considerations

CYP2D6 Metabolism

Bupropion is a strong CYP2D6 inhibitor, which increases plasma levels of dextromethorphan (the intended effect in Auvelity) but also increases levels of SSRIs metabolized by CYP2D6 2, 4. SSRIs with significant CYP2D6 metabolism include:

• Fluoxetine 2
• Paroxetine 2
• Sertraline 2

This interaction may increase SSRI levels and further elevate serotonin syndrome risk 4. Case reports document serotonin syndrome with bupropion-SSRI combinations, attributed to CYP2D6 inhibition 4.

Safer SSRI Options

Citalopram and escitalopram have the least effect on CYP450 enzymes and lower propensity for drug interactions 2, making them potentially safer choices when combining with Auvelity, though monitoring remains essential.

Evidence from Overdose and Case Reports

Case reports provide important safety signals. Two documented cases of serotonin syndrome involved supratherapeutic dextromethorphan doses (950 ng/mL and 2820 ng/mL; normal <5 ng/mL) combined with therapeutic SSRI levels 5. This suggests that therapeutic doses of both agents together are less likely to cause serotonin syndrome, but the risk is not zero 5.

A case report of serotonin syndrome following aripiprazole reintroduction after dextromethorphan overdose emphasizes the need for adequate washout periods when restarting serotonergic medications after dextromethorphan exposure 6.

Management of Serotonin Syndrome

If serotonin syndrome develops:

• Discontinue Auvelity and the SSRI immediately 1
• Hospital-based treatment with supportive care and continuous cardiac monitoring 2
• Consider cyproheptadine (serotonin antagonist) and benzodiazepines 4

Common Pitfalls to Avoid

1. Do not assume the combination is contraindicated—the FDA label warns of risk but does not prohibit concurrent use 1
2. Do not overlook over-the-counter dextromethorphan in cough/cold preparations, which can add to serotonergic burden 2
3. Do not misinterpret early serotonin syndrome symptoms (confusion, agitation) as worsening depression 4
4. Do not combine with MAOIs—this is an absolute contraindication requiring 14-day washout 2, 1
5. Do not forget that 14% of patients on Auvelity experience dizziness, which requires fall precautions 1

Clinical Algorithm for Concurrent Use

Step 1: Verify no MAOI use in past 14 days 1

Step 2: Screen for other dextromethorphan and bupropion products 1

Step 3: Consider SSRI choice—prefer citalopram/escitalopram if initiating new SSRI 2

Step 4: Educate patient on serotonin syndrome symptoms 1

Step 5: Initiate Auvelity at standard dose (one tablet twice daily, 8 hours apart) 1

Step 6: Monitor intensively for 24-48 hours, then regularly thereafter 2

Step 7: If symptoms develop, discontinue both agents immediately and seek emergency care 1